

Amendments to the Claims

Please amend Claim 10. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-8 Canceled.

9. (Withdrawn) A method of boosting a CD8+ T cell immune response to an antigen in an individual, the method including provision in the individual of a replication-deficient adenoviral vector including nucleic acid encoding the antigen or a CD8+ T cell epitope of said antigen operably linked to regulatory sequences for production of said antigen or epitope in the individual by expression from the nucleic acid, whereby a CD8+ T cell immune response to the antigen previously primed with a non-adenoviral vector in the individual is boosted.

10. (Currently amended) A method of inducing a CD8+ T cell immune response to an antigen in an individual, the method comprising administering to the individual a priming composition comprising ~~the antigen or a CD8+ T cell epitope of said antigen or~~ nucleic acid encoding said antigen or a CD8+ T cell epitope of said antigen and then administering a heterologous boosting composition which comprises a replication-deficient adenoviral vector including nucleic acid encoding said antigen or epitope operably linked to regulatory sequences ~~for production of~~ whereby said antigen or epitope is expressed in the individual ~~by expression from the nucleic acid~~.

11. (Original) A method according to claim 10 wherein the priming composition comprises DNA encoding said antigen or epitope.

12. (Original) A method according to claim 10 wherein the priming composition comprises recombinant Ty-VLP.

13. (Original) A method according to claim 10 wherein the priming composition comprises Modified Virus Ankara (MVA).
14. (Withdrawn) A method according to claim 9 further comprising administration of another, different boosting composition comprising said antigen or epitope.
15. (Withdrawn) A method according to claim 9 wherein the boosting composition is administered intranasally.
16. (Withdrawn) A method according to claim 9 wherein the boosting composition is administered intramuscularly.
17. (Previously presented) A method according to claim 10 wherein the priming composition is a non-adenoviral composition.
18. (Previously presented) A method according to claim 10 wherein the priming composition comprises a viral vector.
19. (Previously presented) A method according to claim 18 wherein the priming composition comprises a vaccinia virus vector.
20. (Previously presented) A method according to claim 18 wherein the priming composition comprises an avipox vector.
21. (Previously presented) A method according to claim 18 wherein the priming composition comprises a herpes virus vector.